论文部分内容阅读
目的:观察麝香保心丸联合常规西药治疗气滞血瘀型老年慢性心力衰竭的临床疗效。方法:按照随机数字表法将本院90例气滞血瘀型老年慢性心力衰竭患者分为对照组与治疗组各45例。对照组给予常规西药治疗,观察组在对照组用药基础上联合麝香保心丸治疗。治疗后观察2组心力衰竭症状和心功能的改善情况;观察2组治疗前后的呼吸困难程度评分和左室射血分数(LVEF)、每搏输出量(SV)的变化;记录2组治疗期间的不良反应发生情况。结果:治疗组总有效率为86.7%,高于对照组的60.0%(P<0.05)。治疗前,2组呼吸困难程度评分及LVEF、SV比较,差异均无统计学意义(P>0.05)。治疗后,2组呼吸困难程度评分均较治疗前下降(P<0.05),LVEF与SV均较治疗前升高(P<0.05);治疗组的呼吸困难程度评分低于对照组(P<0.05),LVEF与SV均高于对照组(P<0.05)。治疗期间,2组均未发生严重不良反应。结论:麝香保心丸联合常规西药治疗气滞血瘀型老年慢性心力衰竭,可有效改善患者的心功能和呼吸困难状况,且用药安全。
Objective: To observe the clinical efficacy of Shexiang Baoxin Pill combined with routine western medicine in treating chronic heart failure of qi stagnation and blood stasis type. Methods: According to the random number table method, 90 cases of chronic obstructive jaundice in elderly patients with qi stagnation and blood stasis were divided into control group and treatment group with 45 cases each. The control group was given conventional Western medicine, and the observation group was treated with “Shexiang Baoxin Pill” on the basis of the control group. After treatment, the improvement of symptoms and heart function were observed in two groups. The scores of dyspnea before and after treatment and the changes of left ventricular ejection fraction (LVEF) and stroke volume (SV) were observed. Two groups of treatment periods Adverse reactions occurred. Results: The total effective rate in the treatment group was 86.7%, which was higher than that in the control group (60.0%, P <0.05). Before treatment, two groups of dyspnea score and LVEF, SV, the difference was not statistically significant (P> 0.05). After treatment, the scores of dyspnea in both groups were significantly lower than those before treatment (P <0.05), and LVEF and SV were significantly higher than those before treatment (P <0.05). The score of dyspnea in treatment group was lower than that in control group ), LVEF and SV were higher than the control group (P <0.05). During treatment, no serious adverse reactions occurred in both groups. Conclusion: Shexiang Baoxin Pill combined with routine western medicine can cure heart failure and dyspnoea in patients with qi stagnation and blood stasis type, and the medication is safe.